Expand all sections

Gozetotide

onbekend

Extended indication Indicated for the identification of prostate specific membrane antigen (PSMA)-positive lesions aft
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Gozetotide
Domain Oncology and Hematology
Reason of inclusion New medicine (specialité)
Main indication Prostate cancer
Extended indication Indicated for the identification of prostate specific membrane antigen (PSMA)-positive lesions after radiolabelling with gallium-68
Proprietary name onbekend
Route of administration Intravenous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date October 2021
Expected Registration November 2022
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.